Is Curia Global profitable in 2026?

Curia is privately held and does not disclose profit figures. It carries a Moody's B3 rating with negative outlook since February 2023 on its first-lien debt, and refinanced its senior secured credit facilities in March 2025, signals of leverage stress rather than confirmed profitability.

Who owns Curia Global?

Curia has been owned by The Carlyle Group and GTCR since a roughly $1.5 billion take-private deal at $21.75 per share in June 2017. Curia's 2024 ESG report confirms its board is chaired by CEO Philip Macnabb with three managers each from GTCR and Carlyle.

Is Curia Global laying off employees or closing plants?

Yes. Curia announced closure of its Burlington, MA facility in January 2026, cutting 81 jobs effective through June 2026, after selling its Grafton, WI site (about 80 employees) to Siegfried in 2024. Third-party data shows headcount down 13.2 percent from 3,833 in 2023 to 3,328 by Q4 2025.

Could AI replace Curia Global's business?

Unlikely for its core business. Curia's sterile fill-finish and GMP manufacturing suites require FDA/EMA licensure and physical capacity that AI cannot replicate. Only early-discovery service lines like medicinal chemistry face partial AI-driven compression; the company's mAb manufacturing suite was reported booked out through 2025.

Who is Curia Global's biggest competitor?

Curia is dwarfed by larger CDMOs including Lonza (about $8.1 billion 2024 revenue), Thermo Fisher's Pharma Services (about $7 billion), and Samsung Biologics (about $3.3 billion), which signed a $1.3 billion manufacturing deal and bought a Rockville, MD site for $280 million in 2025, both per Statista and Pharma Manufacturing reporting.

Is Curia Global a safe company to join right now?

There are warning signs. Curia has been PE-owned by Carlyle and GTCR since 2017 with no IPO path, received a Moody's B3 negative outlook in February 2023, closed its Burlington, MA plant in January 2026 cutting 81 jobs, and job postings fell from 153 in 2023 to 15 in 2025 per Revelio Labs.

Biotech tools companies · subsidiary of The Carlyle Group / GTCR (co-owned private equity consortium) · United States

Curia Global, Inc.

curiaglobal.com ↗

Curia is a private-equity-owned CDMO making drugs and biologics for other companies, formerly AMRI.

Losing its protection

Assessed 24 July 2026 · Evidence as of 24 July 2026

The structural protection is eroding.

On the recordSince 24 July 2026 · Checkable from June 2026 · Every call on the record Checkpoint: Burlington, MA plant closure completes, cutting 81 jobs

The call

Curia's plants and licenses keep AI and startups out, but bigger, better-funded CDMOs and a nine-year-old leveraged buyout are the real pressure on the business.

Curia Global makes medicines for pharmaceutical companies using licensed factories and proven processes that take years and billions of dollars to build, so new competitors cannot easily copy them. The problem is that much bigger companies like Lonza, Thermo Fisher, and Samsung Biologics are spending heavily to build their own factories and grabbing the customers Curia needs to survive. Curia is cutting staff, closing plants, and struggling with debt, while private owners have held the company for nine years with no clear exit plan. The one thing that could change everything is whether Curia can refinance its debt and win back enough major customers from larger rivals before its factories become even less valuable.

Why

AI pressure: None apparent. AI only touches early-stage discovery work here; sterile fill-finish and biologics manufacturing stay gated by FDA validation, not code. Could AI do the core job? Unlikely.

Bigger players: Samsung Biologics, Lonza, Thermo Fisher/Patheon. Samsung's new US biologics site and Lonza/Thermo Fisher capacity are live and courting the same large pharma clients Curia depends on. Could a giant copy it? Probably.

What protects it. FDA and EMA licensed plants with validated processes across 20+ sites, the kind of regulatory footprint that takes years and capital to copy.

What would change this call

Second Moody's downgrade or covenant breach on Curia's refinanced debt within 12 months. Would show financial stress deepening beyond the March 2025 refinance.
Announcement of a second plant closure beyond Burlington, MA in 2026. Would show accelerating consolidation under financial pressure.
A named Curia customer or contract moving to Samsung Biologics' Rockville site or Lonza/Thermo Fisher. Would show direct share loss to bigger, better-funded rivals.

Key numbers

Moody's rated Curia's loan B3, outlook negative (2023-02-07)
Headcount fell 13.2%, from 3,833 to 3,328 (2025-Q4)
Burlington, MA site closing, 81 jobs cut (2026-01-20)

Named risks

Leveraged PE debt structure with B3 negative Moody's outlook since Feb 2023 amid 2026 LBO maturity wall. Severity: high
Losing large biologics contracts to better-capitalized rivals like Lonza, Samsung, Thermo Fisher expanding capacity. Severity: high
Facility closures and headcount contraction, Burlington MA Jan 2026 and Grafton WI 2024, plus 13.2% headcount drop 2023-2025. Severity: medium
Nine-year PE hold since 2017 with no disclosed IPO or sale path, leaving equity exit uncertain. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Lonza Group	gaining on	About $8.1B 2024 revenue vs Curia's mid-tier scale, per Statista as of 2025-11-18
Samsung Biologics	gaining on	Signed $1.3B deal and bought $280M Rockville, MD site for US expansion in 2025-2026
Thermo Fisher Scientific	gaining on	Pharma Services revenue about $7B, several times Curia's estimated scale, as of 2025-11-18
WuXi Biologics	contesting	About $2.6B 2024 revenue, competing in same biologics CDMO tier as of 2025-11-18

Questions people ask

Is Curia Global profitable in 2026?: Curia is privately held and does not disclose profit figures. It carries a Moody's B3 rating with negative outlook since February 2023 on its first-lien debt, and refinanced its senior secured credit facilities in March 2025, signals of leverage stress rather than confirmed profitability.
Who owns Curia Global?: Curia has been owned by The Carlyle Group and GTCR since a roughly $1.5 billion take-private deal at $21.75 per share in June 2017. Curia's 2024 ESG report confirms its board is chaired by CEO Philip Macnabb with three managers each from GTCR and Carlyle.
Is Curia Global laying off employees or closing plants?: Yes. Curia announced closure of its Burlington, MA facility in January 2026, cutting 81 jobs effective through June 2026, after selling its Grafton, WI site (about 80 employees) to Siegfried in 2024. Third-party data shows headcount down 13.2 percent from 3,833 in 2023 to 3,328 by Q4 2025.
Could AI replace Curia Global's business?: Unlikely for its core business. Curia's sterile fill-finish and GMP manufacturing suites require FDA/EMA licensure and physical capacity that AI cannot replicate. Only early-discovery service lines like medicinal chemistry face partial AI-driven compression; the company's mAb manufacturing suite was reported booked out through 2025.
Who is Curia Global's biggest competitor?: Curia is dwarfed by larger CDMOs including Lonza (about $8.1 billion 2024 revenue), Thermo Fisher's Pharma Services (about $7 billion), and Samsung Biologics (about $3.3 billion), which signed a $1.3 billion manufacturing deal and bought a Rockville, MD site for $280 million in 2025, both per Statista and Pharma Manufacturing reporting.
Is Curia Global a safe company to join right now?: There are warning signs. Curia has been PE-owned by Carlyle and GTCR since 2017 with no IPO path, received a Moody's B3 negative outlook in February 2023, closed its Burlington, MA plant in January 2026 cutting 81 jobs, and job postings fell from 153 in 2023 to 15 in 2025 per Revelio Labs.

Timeline

2026-03-19Expanded Glasgow site and enhanced CHO-GSN/TunaCHO cell-line platform, claimed 6x higher titers
2026-01-20Announced Burlington, MA plant closure, cutting 81 jobs effective through June 2026
2025-09-15CEO Macnabb said no further acquisitions planned near-term, pivot from 14 prior deals
2025-03-17Announced expansion of Glasgow, UK sterile fill-finish site
2025-03-07Announced strategic refinancing of senior secured credit facilities
2024Sold Grafton, WI facility (about 80 employees) to Siegfried
2023-02-07Moody's downgraded first-lien term loan to B3 with negative outlook
2021-07Rebranded from AMRI to Curia
2017-06-19Taken private by Carlyle Group and GTCR for about $1.5B ($21.75/share)
1991Founded in Albany, NY as Albany Molecular Research, Inc. (AMRI)

Revision history

24 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

Element Biosciences Charles River Laboratories Bio-Techne Corporation